Reviva seeks FDA feedback on new brilaroxazine formulation for schizophrenia
Reviva Pharmaceuticals reported third quarter 2026 financial results and provided updates on its Phase 3 RECOVER-2 trial, noting that FDA feedback on a new formulation is expected in the fourth quarter and patient enrollment is slated to start in the first half of 2027 pending additional financing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed